Omnicell, Inc. (NASDAQ:OMCL) Chairman Randall A. Lipps sold 40,000 shares of the stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $49.76, for a total value of $1,990,400.00. Following the completion of the sale, the chairman now directly owns 196,551 shares in the company, valued at approximately $9,780,377.76. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Shares of Omnicell, Inc. (NASDAQ:OMCL) traded up 0.51% during trading on Friday, reaching $49.55. The company had a trading volume of 244,016 shares. Omnicell, Inc. has a 12 month low of $30.35 and a 12 month high of $51.98. The stock’s 50-day moving average price is $46.29 and its 200-day moving average price is $41.70. The stock’s market capitalization is $1.86 billion.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.02 EPS for the quarter, hitting the consensus estimate of $0.02. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The firm had revenue of $180.90 million for the quarter, compared to analysts’ expectations of $174.08 million. During the same period in the previous year, the firm posted $0.38 EPS. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. Equities analysts forecast that Omnicell, Inc. will post $1.31 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Rincon Hill News and is the sole property of of Rincon Hill News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://rinconhillneighbors.org/2017/08/19/insider-selling-omnicell-inc-nasdaqomcl-chairman-sells-40000-shares-of-stock-updated-updated.html.
Several research analysts have weighed in on the company. Dougherty & Co lifted their target price on Omnicell from $45.00 to $49.00 and gave the company a “buy” rating in a research note on Friday, July 28th. Piper Jaffray Companies reiterated a “hold” rating and issued a $40.00 target price on shares of Omnicell in a research note on Sunday, July 30th. BidaskClub cut Omnicell from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Craig Hallum raised their price target on Omnicell from $46.00 to $52.00 and gave the company a “buy” rating in a report on Friday, July 28th. Finally, Zacks Investment Research raised Omnicell from a “sell” rating to a “hold” rating in a report on Tuesday, July 4th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $49.00.
A number of large investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. purchased a new position in Omnicell during the first quarter valued at $125,000. LS Investment Advisors LLC raised its position in Omnicell by 136.3% in the first quarter. LS Investment Advisors LLC now owns 3,571 shares of the company’s stock valued at $145,000 after buying an additional 2,060 shares in the last quarter. State of Alaska Department of Revenue raised its position in Omnicell by 3.0% in the first quarter. State of Alaska Department of Revenue now owns 4,080 shares of the company’s stock valued at $165,000 after buying an additional 120 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new position in Omnicell during the first quarter valued at $170,000. Finally, Turner Investments LLC purchased a new position in Omnicell during the second quarter valued at $181,000. 96.35% of the stock is currently owned by hedge funds and other institutional investors.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with our FREE daily email newsletter.